Cite

    Bokemeyer, B., Hlavaty, T., Allez, M., Selema, P., Moosavi, S., Cadatal, M. J., Fowler, H., Cheung, R., Lukas, M., & Gisbert, J. P. (n.d.). p590 An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab. Journal of Crohn's and colitis, 13, S410. http://access.bl.uk/ark:/81055/vdc_100094050582.0x00000a